Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.

[1]  M. Behrends,et al.  The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts , 2003, Intensive Care Medicine.

[2]  W. Colucci,et al.  Sustained Hemodynamic Effects of Intravenous Levosimendan , 2003, Circulation.

[3]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[4]  P. Pentikäinen,et al.  Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure , 2002, Journal of clinical pharmacology.

[5]  S. Adamopoulos,et al.  A glossary of circulating cytokines in chronic heart failure , 2001, European journal of heart failure.

[6]  S. Gottlieb,et al.  Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure , 2000, Circulation.

[7]  W. Paulus.  How are cytokines activated in heart failure? , 1999, European journal of heart failure.

[8]  Y. Kihara,et al.  New insights into the pathophysiological role for cytokines in heart failure. , 1999, Cardiovascular research.

[9]  S. Yamaguchi,et al.  Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure. , 1999, The American journal of cardiology.

[10]  J. Parissis,et al.  Tumor Necrosis Factor-a Serum Activity During Treatment of Acute Decompensation of Cachectic and Non-Cachectic Patients with Advanced Congestive Heart Failure , 1999 .

[11]  G. Hasenfuss,et al.  Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. , 1998, Circulation.

[12]  M. Sunagawa,et al.  The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. , 1997, The Journal of pharmacology and experimental therapeutics.

[13]  M. Sunagawa,et al.  Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. , 1997, European journal of pharmacology.

[14]  S. Yamaguchi,et al.  Serum levels of soluble form of Fas molecule in patients with congestive heart failure. , 1997, The American journal of cardiology.

[15]  C. Lavie,et al.  The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. , 1996, Chest.

[16]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.

[17]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[18]  K. Lipscomb,et al.  Relation of left ventricular shape, function and wall stress in man. , 1974, The American journal of cardiology.